Navigation Links
Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
Date:1/9/2012

SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Ambit Biosciences Corporation today announced that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 10 a.m. PST on Thursday, January 12, at The Westin St. Francis in San Francisco. Michael A. Martino, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences

Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipeline includes AC430, an oral JAK2 inhibitor, and AC480, a pan-HER inhibitor.

Ambit's preclinical portfolio includes, CEP-32496, a BRAF inhibitor licensed to Cephalon, and a proprietary CSF1R inhibitor program. For more information, visit

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference
2. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
3. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. Ambit Biosciences Strengthens Board of Directors and Executive Team
6. Ambit Biosciences Initiates Two Phase I Clinical Trials
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... HILDEN , Germany and ... -- , Collaboration aims to ... plasma samples to guide the use of IRESSA  for ... test will build on QIAGEN,s FDA-approved  therascreen   EGFR test ... QIAsymphony family of automated instruments  Project enabled ...
Breaking Medicine Technology:PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
... Foundation Radiology Group (FRG), the region,s premier provider ... it has been named the Hospital Council of Western ... Pittsburgh-based radiology practice that brings the expertise of a ... across Pennsylvania and the tri-state area. By partnering with ...
... Oct. 18 Fenwal, Inc., a global medical ... safety and availability, announced today it has signed ... sell, market and distribute the AccuVein AV300 vein ... North America. (Photo:   http://photos.prnewswire.com/prnh/20101018/CG83159 ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 2Fenwal Named Exclusive Provider of AccuVein's Award-Winning Vein Illumination Device for Blood and Plasma Centers 3
(Date:7/28/2014)... 28, 2014 TherapySites, the ... professionals, announced today its affiliation with the Illinois ... new relationship allows TherapySites to continue to extend their ... and promotional offers. , “There has been a fundamental ... With nearly 3 billion Internet users, it is ...
(Date:7/28/2014)... Footwear etc. is delighted to showcase ... With shoes, sandals, and boots that have only increased ... handmade comfort shoes and quality that is ... to rely on the superb value, durability, and high-end ... sandals contain the highest quality materials available, and as ...
(Date:7/28/2014)... San Antonio, TX (PRWEB) July 28, 2014 ... July 28, the Editorial Board of Living with ... that focuses on disabling digestive disorders that include hepatitis, ... malnutrition. , The important new article highlights ... Disability award, those afflicted with hepatitis and other disabling ...
(Date:7/28/2014)... 2014 According to the Drama Method Pdf ... guide that helps women easily get the attention of the ... reveals in its review that this book can teach ladies ... man. The book also instructs them how to conquer a ... its Drama Method review that this book is divided into ...
(Date:7/28/2014)... GA (PRWEB) July 28, 2014 Mitul ... the nation gathered at the MGE Management Experts Benefit ... and community leaders joined the Dentists to raise funds ... the Boys and Girls Clubs and Youth Programs across ... of young people with books and audio books to ...
Breaking Medicine News(10 mins):Health News:TherapySites (Websites for Therapists) Partners with the Illinois Association for Marriage and Family Therapy 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 2Health News:Footwear etc. Highlights Phenomenal Models of Mephisto Shoes 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... in Sweden shows that phthalates from PVC flooring materials is ... cause asthma and allergies, as well as other chronic diseases ... softening agents with food but also by breathing and through ... that occur in construction materials and a great number of ...
... , TUESDAY, May 22 (HealthDay News) -- Patients undergoing ... threading a camera through the colon to detect precancerous ... found that patients overwhelmingly preferred colonoscopy to the less ... Colonoscopy has long been the standard of care for ...
... inhaled corticosteroids in patients with respiratory disorders who develop ... incidence and severity of parapneumonic effusion, according to a ... effusion is a type of pleural effusion (excess fluid ... space that surrounds the lungs) that arises as a ...
... researchers will present findings on prostate cancer risk, screening, ... of the American Urological Association May 19-23 in Atlanta. ... expert comment for reporters covering the conference. Mayo ... dates include: No negative impact on overall ...
... (RCTs) are critical for determining effectiveness of medical therapies, ... these studies compared with other western countries, states an ... Journal ). Dr. Salim Yusuf, McMaster University and ... University of British Columbia, argue in the analysis and ...
... Ky. (May 17, 2012) The University of Kentucky Markey ... a deadly blood and bone marrow disease often caused by ... Edward P. Evans Foundation, along with a $1.25 million donor ... Evans Foundation grant will fund five research labs over five ...
Cached Medicine News:Health News:Phthalates in PVC floors taken up by the body in infants 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
... Stent may become a practice-changing technology for ... treatment of lower urinary tract symptoms (LUTS). ... retention , Men unfit for surgery , ... therapy - TUMT, TUNA, Brachytherapy, Cryotherapy , ...
Medicine Products: